Patents by Inventor Lawrence C. Sowers

Lawrence C. Sowers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Circumvention of human tumor drug resistance
    Publication number: 20020055470
    Abstract: A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.
    Type: Application
    Filed: June 26, 2001
    Publication date: May 9, 2002
    Applicant: CITY OF HOPE
    Inventors: Kevin J. Scanlon, Lawrence C. Sowers
  • Synthesis of 4-alkoxy-5-fluoro-2'-deoxyuridine and its incorporation into oligonocleotides
    Patent number: 5663323
    Abstract: A synthesis of 5-fluoro-2'-ideoxycytidine, of oligonucleotides containing 5-fluoro-2'-deoxycytidine and of certain novel 4-alkoxy-5-fluoro-2'-deoxyuridines is disclosed. These 4-alkoxy compounds are useful intermediates for the preparation of other 4-substituted, 5-fluoro pyrimidine deoxynucleosides, and spontaneously hydrolyze in target cells to form FdU and derivatives thereof.
    Type: Grant
    Filed: March 12, 1996
    Date of Patent: September 2, 1997
    Assignee: City of Hope
    Inventor: Lawrence C. Sowers
  • Circumvention of human tumor drug resistance
    Patent number: 5585363
    Abstract: A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: December 17, 1996
    Assignee: City of Hope
    Inventors: Kevin J. Scanlon, Lawrence C. Sowers
  • 4-ethoxy-5-fluoro-2'-deoxyuridine
    Patent number: 5530110
    Abstract: 4-Ethoxy-5-fluoro-2'-deoxyuridine is disclosed as an intermediate in the synthesis of 5'-fluoro-2'-deoxycytidine. The treatment of 4-ethoxy-5-fluoro-2'-deoxyuridine with methanolic ammonia eliminates the side product of 5-fluoro-2'-deoxyuridine which occurs when 4-methoxy-5-fluoro-2'-deoxyuridine is used as the reactant. 4-Ethoxy-5-fluoro-2'-deoxyuridine is also a prodrug of 5-fluoro-2'-deoxyuridine which is substantially less toxic than parent free nucleoside 5-fluoro-2'-deoxyuridine.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: June 25, 1996
    Assignee: City of Hope
    Inventor: Lawrence C. Sowers
  • Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
    Patent number: 5166140
    Abstract: A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.
    Type: Grant
    Filed: October 13, 1989
    Date of Patent: November 24, 1992
    Assignee: City of Hope
    Inventors: Kevin J. Scanlon, Lawrence C. Sowers